Marshall Wace North America’s Prestige Consumer Healthcare PBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
– Sell
-34,972
Closed -$1.28M – 1389
2020
Q1
$1.28M Buy
+34,972
New +$1.36M 0.01% 568
2019
Q4
– Sell
-1,992
Closed -$69K – 1522
2019
Q3
$69K Buy
+1,992
New +$65.6K ﹤0.01% 1115
2019
Q1
– Sell
-38,027
Closed -$1.17M – 1818
2018
Q4
$1.17M Buy
+38,027
New +$1.39M 0.01% 574
2018
Q3
– Sell
-8,535
Closed -$327K – 1255
2018
Q2
$327K Buy
+8,535
New +$288K ﹤0.01% 1166
2018
Q1
– Sell
-141,339
Closed -$6.28M – 1630
2017
Q4
$6.28M Buy
+141,339
New +$6.44M 0.03% 513
2017
Q3
– Sell
-4,839
Closed -$257K – 1445
2017
Q2
$257K Buy
+4,839
New +$259K ﹤0.01% 1183

Other funds holding PBH

Marshall Wace North America's PBH Position: Q2 2020 in Review

Marshall Wace North America sold out of Prestige Consumer Healthcare (PBH) in Q2 2020, closing a stake of 34,972 shares — an estimated $1.28M sold.

Marshall Wace North America first reported a position in PBH in Q2 2017 and held it in 6 quarters. The position peaked at $6.28M in Q4 2017. 253 funds tracked by Wall St. Rank hold PBH as of Q2 2020.

  • Marshall Wace North America reported no remaining Prestige Consumer Healthcare position as of Q2 2020 after selling out during the quarter.
  • Marshall Wace North America sold 34,972 Prestige Consumer Healthcare shares in Q2 2020, an estimated $1.28M.
  • Marshall Wace North America first reported a position in Prestige Consumer Healthcare in Q2 2017 and held it in 6 quarters.
  • Marshall Wace North America's Prestige Consumer Healthcare position peaked at $6.28M in Q4 2017.
  • 253 funds tracked by Wall St. Rank held Prestige Consumer Healthcare as of Q2 2020.

Based on Marshall Wace North America's 13F filing for Q2 2020, filed 13 Aug 2020.